

references

- American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA: American Cancer Society, 2014.
- Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. *Curr Oncol Rep* 2011; 13: 195–205.
- Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. *Science* 1981; 212: 53–55.
- Koprowski H, Steplewski Z, Mitchell K et al. Colorectal carcinoma antigens detected by hybridoma antibodies. *Somatic Cell Genet* 1979; 5: 957–971.
- Boeck S, Stieber P, Holdenrieder S et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. *Oncology* 2006; 70: 255–264.
- Bauer TM, El-Rayes BF, Li X et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. *Cancer* 2013; 119: 285–292.
- Ko AH, Hwang J, Venook AP et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. *Br J Cancer* 2005; 93: 195–199.
- Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. *J Gastrointest Surg* 1997; 1: 106–112.
- Saad ED, Machado MC, Wajsbrodt D et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. *Int J Gastrointest Cancer* 2002; 32: 35–41.
- Stemmler J, Stieber P, Szymala AM et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? *Onkologie* 2003; 26: 462–467.
- Ziske C, Schlie C, Gorschluter M et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. *Br J Cancer* 2003; 89: 1413–1417.
- Reni M, Cereda S, Balzano G et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. *Cancer* 2009; 115: 2630–2639.
- Hess V, Glimelius B, Grawe P et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. *Lancet Oncol* 2008; 9: 132–138.
- Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; 369: 1691–1703.
- Goldstein D, El-Maraghi RH, Hammel P et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. *J Natl Cancer Inst* 2015; 107: dju413.
- Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase VII trial. *J Clin Oncol* 2011; 29: 4548–4554.
- Tabernero J, Chiorean EG, Infante R et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. *Oncologist* 2015; 20: 143–150.
- Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 2000; 92: 205–216.
- Robert M, Jarlier M, Conroy T et al. Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4). *ASCO Meeting Abstracts* 2014. *J Clin Oncol* 2014; (5s suppl): abstr 4115.

Annals of Oncology 27: 660–667, 2016
doi:10.1093/annonc/mdw010
Published online 17 January 2016

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction

F. Klevebro^{1*}, G. Alexandersson von Döbeln², N. Wang³, G. Johnsen⁴, A.-B. Jacobsen⁵, S. Friesland², I. Hatlevoll⁶, N. I. Glenjen⁷, P. Lind⁸, J. A. Tsai¹, L. Lundell¹ & M. Nilsson¹

¹Division of Surgery, Department of Clinical Science Intervention and Technology, Karolinska Institutet and Centre for Digestive Diseases, Karolinska University Hospital, Stockholm; ²Departments of ²Oncology; ³Pathology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; ⁴Department of Gastrointestinal Surgery, St Olavs Hospital, Trondheim University Hospital, Trondheim; ⁵Department of Oncology, Oslo University Hospital, Oslo; ⁶Department of Oncology, St Olavs Hospital, Trondheim University Hospital, Trondheim; ⁷Department of Oncology, Haukeland University Hospital, Bergen, Norway; ⁸Department of Oncology, Mälarsjukhuset Eskilstuna, Karolinska Institutet, Stockholm, Sweden

Received 13 November 2015; revised 16 December 2015; accepted 18 December 2015

Background: Neoadjuvant therapy improves long-term survival after oesophagectomy, treating oesophageal cancer, but the evidence to date is insufficient to determine which of the two main neoadjuvant therapy types, chemotherapy (nCT) or chemoradiotherapy (nCRT), is more beneficial. We aimed to compare the effects of nCT with those of nCRT.

*Correspondence to: Dr Fredrik Klevebro, Centre for Digestive Diseases, Karolinska University Hospital, K53 14186 Stockholm, Sweden. Tel: +46-8-585-800-00; Fax: +46-8-585-863-66; E-mail: fredrik.klevebro@ki.se